United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

organon pharma (uk) ltd - finasteride - oral tablet - 1mg

Canada - English - Health Canada

vertex pharmaceuticals (canada) incorporated - tezacaftor; ivacaftor; ivacaftor - tablet - 100mg; 150mg; 150mg - tezacaftor 100mg; ivacaftor 150mg; ivacaftor 150mg - cystic fibrosis transmembrane conductance regulator correctors

European Union - English - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - cystic fibrosis - other respiratory system products - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.

Canada - English - Health Canada

vertex pharmaceuticals (canada) incorporated - lumacaftor; ivacaftor - granules - 100mg; 125mg - lumacaftor 100mg; ivacaftor 125mg - cystic fibrosis transmembrane conductance regulator correctors

Canada - English - Health Canada

vertex pharmaceuticals (canada) incorporated - lumacaftor; ivacaftor - granules - 150mg; 188mg - lumacaftor 150mg; ivacaftor 188mg - cystic fibrosis transmembrane conductance regulator correctors

Singapore - English - HSA (Health Sciences Authority)

medtronic international, ltd. - orthopaedics - when intended as an adjuct to fusion in skeletally mature patients using allograft and/or autograft of the occipitocervical spine, cervical spine, and the thoracic spine, (occiput-t3), the vertex® reconstruction system is indicated for the following: ddd (neck pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies), spondylolisthesis, spinal stenosis, fracture, dislocation, failed previous fusion and/or tumors.

European Union - English - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - cystic fibrosis - other respiratory system products - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

Canada - English - Health Canada

vertex pharmaceuticals (canada) incorporated - tezacaftor; ivacaftor; ivacaftor; elexacaftor - tablet - 50mg; 75mg; 150mg; 100mg - tezacaftor 50mg; ivacaftor 75mg; ivacaftor 150mg; elexacaftor 100mg - cystic fibrosis transmembrane conductance regulator correctors

Canada - English - Health Canada

vertex pharmaceuticals (canada) incorporated - ivacaftor - granules - 25mg - ivacaftor 25mg - cystic fibrosis transmembrane conductance regulator potentiators

Canada - English - Health Canada

vertex pharmaceuticals (canada) incorporated - tezacaftor; ivacaftor; ivacaftor; elexacaftor - tablet - 25mg; 37.5mg; 75mg; 50mg - tezacaftor 25mg; ivacaftor 37.5mg; ivacaftor 75mg; elexacaftor 50mg